Ampersand Biomedicines

Ampersand Biomedicines is a biotechnology company that focuses on developing innovative therapeutic solutions aimed at treating diseases directly at the site of action. Utilizing its proprietary Address, Navigate, Design (AND)™ Platform, the company integrates a localizing element for precision targeting with an actuator tailored for specific disease modification. This approach allows for the exploration and treatment of a wide array of diseases across various areas of the body, enhancing the potential for effective medical interventions.

http://www.ampersand.bio

https://linkedin.com/company/ampersand-biomedicines

https://twitter.com/ampersandbio

Raffi Afeyan

Co-Founder and Chief Innovation Officer

1 past transactions

AbCheck

Acquisition in 2024

AbCheck specializes in the discovery and optimization of human therapeutic antibodies through a versatile antibody discovery platform. Founded in 2009 as a spin-out of Affimed's technology discovery platform, the company collaborates with partners to provide drug candidates under flexible terms, including royalty-free agreements. AbCheck generates target-specific human antibody domains that can be utilized in various therapeutic formats. By employing both de novo antibody discovery from animals and libraries of human antibodies, including humanized libraries cloned from immunized rabbits, the company enables clients to identify unique antibody sequences tailored for cancer immunotherapy. As a wholly owned subsidiary of Affimed GmbH, AbCheck contributes to the advancement of highly targeted cancer treatments.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.